Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 5, 2025
Reporting period
Not applicable
Filed with the SEC
Dec 9, 2025
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0002009236-25-000008
Filed / recorded
Dec 9, 2025, 10:38 PM UTC
Added to OQRO
Oct 2, 2026, 12:28 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
REGENERON PHARMACEUTICALS, INC.
Issuer CIK
872589
Ticker
REGN
Reporting person
Jason Pitofsky
Relationship
Officer
Officer title
VP Controller
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Dec 5, 2025
Transaction code
A
Shares / units
2,064
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
6,297
Ownership form
Direct
Amendment
No
Footnotes from the filing
Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 5, 2027 and 50% on December 5, 2029.